Compare Eli Lilly And Co (LLY) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B). The key difference: Eli Lilly And Co is far larger — about 21.8× iShares 20 Plus Year Treasury Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| LLY | TLT | |
|---|---|---|
Market Cap | $1.04T | $47.61B |
Volume | 3,064,878 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $1.28K | $92.06 |
52-Week Low | $799.57 | $77.11 |
Typical Hold Time | 93 Days | 83 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.87, down 46% over five years amid a historic bond market selloff. The technical outlook is bearish with moving averages signaling continued pressure, while oscillators remain neutral. Recent news highlights Treasury yields reaching multi-decade highs above 5.3%, creating headwinds for long-duration bond funds as investors face elevated interest rate expectations.
The ETF faces significant interest rate risk with the Federal Reserve maintaining higher rates. Current yields above 5% offer attractive income but price depreciation remains a concern. Key risks include prolonged high inflation, further Fed tightening, and economic growth surprises that could extend the bond market downturn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
